FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder | FDA - FDA.gov

The FDA approved the first treatment for eosinophilic esophagitis, a chronic immune disorder, in adults and pediatric patients

For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and … [+4529 chars]

full article...